Wall Street equity analysts tracking Compass Pathways PLC (NASDAQ: CMPS) maintain a consensus rating leaning toward a Buy, supported by developments in its clinical trials for mental health therapeutics. However, because pre-revenue biotech firms experience high volatility ahead of regulatory approvals, investors must weigh clinical trial risks carefully.